Reported Late Tuesday, FDA Advisory Committee Votes In Favor Of Abbott's First-of-Its-Kind TriClip™ System To Treat People With A Leaky Tricuspid Heart Valve
Portfolio Pulse from Benzinga Newsdesk
The FDA Advisory Committee has voted in favor of Abbott's TriClip System, a first-of-its-kind device designed to treat tricuspid regurgitation, based on positive data from the TRILUMINATE pivotal trial. Although still investigational in the U.S., TriClip is approved in over 50 countries and has been used to treat over 10,000 patients globally.
February 14, 2024 | 6:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbott's TriClip System receives favorable vote from FDA Advisory Committee for treating tricuspid regurgitation, showcasing its global impact and potential U.S. market entry.
The positive vote from the FDA Advisory Committee significantly boosts the prospects of Abbott's TriClip System in the U.S. market. Given the system's approval in over 50 countries and its successful treatment of over 10,000 patients, this endorsement is likely to be viewed positively by investors and could lead to an uptick in Abbott's stock price in the short term. The data from the TRILUMINATE trial, demonstrating safety, effectiveness, and quality-of-life benefits, further supports the potential for market adoption and revenue growth from this innovative product.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100